Which Works Better: Single vs Dual Hormone Approach?
Ozempic or Wegovy vs Mounjaro: Key Mechanism Differences
When considering Ozempic or Wegovy versus Mounjaro, the fundamental difference lies in their hormonal mechanisms. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics one natural fullness hormone, whilst Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist targeting two separate hormone pathways. This dual mechanism may offer different appetite control patterns, though both treatments work by reducing hunger signals to the brain and promoting satiety after smaller meals.
The choice between single-pathway Wegovy and dual-pathway Mounjaro often depends on individual response patterns and tolerability profiles. Both prescription-only medicines require careful dose escalation under medical supervision, with your prescriber determining which mechanism aligns best with your medical history and weight management goals. EverydayMeds supplies both options through our GPhC #9012878 registered pharmacy, allowing your healthcare provider to switch between treatments if needed during your weight management journey.
Wegovy vs Mounjaro Pricing: Complete UK Cost Comparison
EverydayMeds offers transparent pricing for both Wegovy and Mounjaro, with starter doses beginning at £79.99 for Wegovy 0.25mg using code FIRST40 for new customers. Wegovy's five-dose escalation pathway ranges from £79.99 (0.25mg) to £209.99 (2.4mg maintenance), whilst Mounjaro follows a six-dose schedule with different pricing tiers. Returning customers can apply code DOSE25 at checkout for continued savings across both treatment options.
Our bundle options provide convenient multi-month supplies for both treatments, including the Intro Duo (£169.99) covering your first two Wegovy doses, and the Ultimate Stability Trio (£649.99) providing three months of maintenance supply. These bundles ensure treatment continuity whilst reducing ordering frequency, particularly important given both medications require consistent weekly administration. Both Wegovy and Mounjaro qualify for our express prescriber review service, minimising treatment delays when transitioning between dose levels.
Clinical Evidence: STEP vs SURMOUNT Trial Data
Clinical trials demonstrate both treatments' efficacy when used alongside reduced-calorie diets and increased physical activity. Wegovy's STEP programme showed patients achieving approximately 15% average weight loss at 68 weeks in STEP 1 (Wilding et al., NEJM, 2021), whilst the STEP 2 trial demonstrated around 9.6% weight reduction in participants with type 2 diabetes. These results reflect carefully controlled trial conditions with intensive lifestyle interventions.
Mounjaro's SURMOUNT trials evaluated tirzepatide's dual mechanism approach, though direct comparison between trial results isn't appropriate due to different study designs, participant populations, and endpoints. Both treatments showed cardiovascular benefits in their respective outcome studies, with Wegovy's SELECT trial demonstrating a 20% reduction in major cardiovascular events. Individual responses vary significantly, making prescriber guidance essential when choosing between these options.
How Wegovy Works: GLP-1 Receptor Mechanism Explained
Wegovy functions as a GLP-1 receptor agonist, mimicking glucagon-like peptide-1, a hormone naturally released by your intestines after eating. This mechanism targets specific brain centres controlling appetite and satiety, potentially reducing food cravings and promoting feeling full after smaller portions. The once-weekly injection using Novo Nordisk's FlexTouch pen device maintains consistent hormone levels throughout the week. Unlike oral medications, injectable delivery bypasses digestive breakdown, ensuring reliable absorption. The treatment requires mandatory dose escalation over 16 weeks, starting at 0.25mg and increasing gradually to minimise gastrointestinal side effects whilst building therapeutic effectiveness.
EverydayMeds Ordering Process: Assessment to Delivery
Our streamlined process begins with a 3-minute online clinical assessment covering your medical history, current medications, and weight management goals for either Wegovy or Mounjaro. Qualified prescribers review applications within 3 working days (or 24 hours with express service), ensuring appropriate treatment selection and dosing recommendations. Once approved, we dispatch your prescription-only medicine via next-day delivery using temperature-controlled packaging to maintain cold-chain integrity. Our pharmacy team provides ongoing support throughout your treatment journey, including dose escalation guidance and storage advice. All orders include comprehensive patient information leaflets and injection technique resources to optimise treatment outcomes.
Storage and Practical Considerations for Both Treatments
Both Wegovy and Mounjaro require refrigeration at 2-8°C before first use, though Wegovy offers superior travel flexibility with 6 weeks room temperature stability below 30°C versus Mounjaro's 21-day limit. This storage advantage makes Wegovy more suitable for extended travel or temperature-sensitive situations. Both treatments use pre-filled pen devices with different mechanisms - Wegovy's FlexTouch system versus Mounjaro's KwikPen design. Weekly injection timing should remain consistent, with both medications typically administered on the same day each week. Dose escalation schedules differ significantly: Wegovy follows a structured 16-week pathway to maintenance, whilst Mounjaro uses a flexible escalation approach based on individual tolerability and response.
Ozempic or Wegovy: Understanding the Critical Distinction
Many patients initially search for "Ozempic or Wegovy" without realising these contain identical semaglutide but serve different licensed purposes. Ozempic is specifically licensed for type 2 diabetes management, whilst Wegovy received separate MHRA approval for weight management in adults with obesity or overweight with complications. Promoting Wegovy for weight management constitutes illegal off-label advertising in the UK, making Wegovy the only legally prescribed semaglutide option for weight management.
This distinction becomes crucial when comparing treatment options, as Mounjaro competes directly with Wegovy in the licensed weight management space. Both Wegovy and Mounjaro underwent rigorous clinical trials specifically for weight management, ensuring appropriate safety and efficacy data for this indication. EverydayMeds exclusively supplies Wegovy for weight management purposes, maintaining full compliance with MHRA licensing requirements whilst offering the proven semaglutide mechanism through its properly licensed formulation.
Making Your Choice: Expert Clinical Support Available
Selecting between Wegovy's established GLP-1 mechanism and Mounjaro's innovative dual approach requires personalised medical assessment considering your health profile, previous treatment responses, and lifestyle factors. Our prescribers evaluate contraindications, drug interactions, and individual risk factors to recommend the most appropriate starting option. Both treatments are available through EverydayMeds with identical clinical support standards, ensuring seamless transitions if treatment changes become necessary. Apply code FIRST40 for new customers or DOSE25 for returning patients when ordering either treatment through our secure platform at https://everydaymeds.co.uk/collections/weight-loss, with expert clinical guidance throughout your weight management journey.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
